C-2799 Capecitabine, >99% [Capecitabin] [Capecitibine] [Capecytabine] [Capiibine] [Captabin] [Caxeta] [Ro 09-1978] [Xabine] [Xeloda] M.W. 359.35 C15H22FN3O6 [154361-50-9] M.I. 14: 1754 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 12.5 mg/mL with slight warming; soluble in water at 2 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Capecitabine is a pre-prodrug of 5-fluorouracil (5-FU). After oral uptake, capecitabine is first metabolized to 5′-deoxy-5-fluorocytidine (5′-DFCR), which happens mainly in the liver by carboxyl-esterase. The metabolite is converted to 5′-deoxy-5-fluoro-uridine (5′-DFUR) by cytidine deaminase in liver and tumor tissue. Then 5′-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Miwa, M., et al. “Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.” Eur. J. Cancer 34: 1274-1281 (1998). •Capecitabine inhibits tumor growth by incorporation of 5-FU into RNA and DNA and inhibition of thymidylate synthase. Schellens, J.H. “Capecitabine.” Oncologist 12: 152-155 (2007). •Capecitabine is the active ingredient in the drug sold under the trade name Xeloda®. This drug has been approved in at least one country for use in patients with metastatic breast and colorectal cancers. NOTE: The capecitabine product sold by LC Laboratories is NOT Xeloda®, and is NOT for human use. •Other CAS numbers previously assigned to capecitabine, 158798-73-3 and 958887-39-3, have been deleted by CAS and are no longer in use. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use./b>. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses
